Maresin 2

Maresin 2 (2 ng/g body weight; intraperitoneal injection; single dose; 24 h post-trauma) significantly increases the colonic mucosal wound healing rate to 47.67% at 72 h post-injury in a biopsy-induced colonic mucosal injury model of C57BL/6 mice^[1].
Maresin 2 (2 ng/g body weight; intraperitoneal injection; administered on days 0, 2, 4, 6, and 8 for a total of 5 times) significantly reduces disease activity and colonic mucosal injury in the 5% DSS-induced colitis model of C57BL/6 mice, with a histological colitis score of 3.951^[1].
Maresin 2 (1-10 ng per rat; i.p.; administered daily for 2 consecutive days followed by every other day; on days 14-32 after streptozotocin induction) significantly alleviates mechanical hyperalgesia in streptozotocin-induced male Wistar diabetic rats (at doses of 1, 3 and 10 ng/rat), improves anxiety-like behavior at a dose of 3 ng/rat, and normalizes IL-1β levels in the spinal cord and prefrontal cortex^[2].
Maresin 2 (1 ng per mouse; intravenous injection; for 4 consecutive days) exerts a protective effect on ovalbumin-induced asthma in female BALB/c mice, and alleviates airway inflammation, Th2 immune response, NLRP3 inflammasome activation and oxidative stress^[3].
Maresin 2 (1-10 ng; intrathecal; single injection) significantly attenuates the acute and inflammatory phases of formalin-induced orofacial nociception in rats^[5].
Maresin 2 (10 ng; administered twice on postoperative day 1 and day 3) prevents the development of thermal hyperalgesia and mechanical hyperalgesia in a rat model of postoperative orofacial pain^[5].